ÂÜÀòÂÒÂ×

Dr. Ludwig is a recognized leader in the biopharmaceutical industry, having supported the development and successful launch of several biologic oncology products including Erbitux, Cyramza, Portrazza, and Lartruvo, as well as the clinical advancement of a number of other therapeutic antibodies Over the course of his career. Most recently, he served as the chief science and technology officer for Actinium Pharmaceuticals. Prior to Actinium, Dr. Ludwig served as the chief scientific officer, vice president, of oncology discovery research biologics technology, and a member of the oncology research senior leadership team at Eli Lilly and Company. Prior to the acquisition of ImClone by Eli Lilly, he held the position of head of molecular & cellular engineering at ImClone Systems Incorporated. Dr. Ludwig trained as a postdoctoral associate in the DNA Damage and Repair Group of the Los Alamos National Laboratory and as a postdoctoral fellow in the Department of Molecular Genetics, Biochemistry, and Microbiology at the University of Cincinnati College of Medicine. He holds a B.S. in biology with a concentration in microbiology from James Madison University and received his Ph.D. in Microbiology from East Carolina University.